4 of 15

	Products
	Vioxx rofecoxib • osteoarthritis • acute pain Cozaar losartan potassium • high blood pressure Hyzaar losartan potassium and hydrochlorothiazide • high blood pressure Fosamax alendronate sodium • treatment and prevention of postmenopausal osteoporosis • reduce osteoporotic fracture risk in postmenopausal women • treatment of male osteoporosis to increase bone mass • treatment of glucocorticoid-induced osteoporosis • Paget’s disease of the bone Zocor simvastatin • elevated cholesterol • associated total/coronary mortality1 • raise HDL cholesterol • reduce triglycerides • reduce stroke risk1 Singulair montelukast sodium • chronic asthma–adults and in children as young as age 2
	Aggrastat tirofiban hydrochloride • unstable angina • non-Q-wave myocardial infarction Cancidas caspofungin acetate • treatment of invasive aspergillosis in patients who did not respond to or were intolerant of other antifungal therapies Comvax Haemophilus b conjugate and hepatitis B (recombinant) vaccine • Haemophilus influenzae type b disease and hepatitis B disease Cosopt dorzolamide hydrochloride and timolol maleate • lower intraocular pressure Crixivan indinavir sulfate • HIV infection Invanz ertapenem sodium • treatment of many aerobic and anaerobic bacteria, particularly community acquired, such as complicated intra-abdominal and complicated skin and skin structure infections Maxalt rizatriptan benzoate • acute migraine Pepcid AC2 famotidine • heartburn Propecia finasteride • treatment of male pattern hair loss Proscar finasteride • treatment of symptomatic benign prostate enlargement Stocrin3 efavirenz • HIV infection Merck’s efforts in HIV research reflect our long-standing commitment to the development of life-saving medicines and vaccines: We are in early clinical trials for a gene-based HIV vaccine. Daniel Freed, research immunologist, removes an HIV vaccine clinical sample from liquid nitrogen freezer storage at our West Point, Pa., laboratories. Trusopt dorzolamide hydrochloride • lower intraocular pressure Timoptic-XE timolol maleate ophthalmic gel forming solution • lower intraocular pressure Vaqta inactivated hepatitis A vaccine • hepatitis A Varivax varicella virus vaccine live [Oka/Merck strain] • chickenpox *This list excludes a number of older Company products introduced before 1990 1 In patients with coronary heart disease and elevated cholesterol 2 Marketed by the Johnson & Johnson • Merck Consumer Pharmaceuticals Co. 3 Efavirenz is marketed by Bristol-Myers Squibb as Sustiva in the U.S., Canada and certain European countries and by Merck in the rest of the world as Stocrin
	Major filings made in 2001 or expected in 2002 Arcoxia (etoricoxib)4 • osteoarthritis, rheumatoid arthritis, acute pain, chronic pain and dysmenorrhea (menstrual pain) Substance P antagonist5 • prevention of chemotherapy-induced nausea and vomiting Zetia (ezetimibe)6 monotherapy and co-administration with statins • elevated cholesterol levels Cozaar (supplemental indication) • reduction in progression of renal disease in Type 2 diabetes Cancidas (supplemental indications) • esophageal Candida infection • invasive Candida infection Singulair (supplemental indication) • allergic rhinitis Zocor (supplemental indication) • reduce the risk of heart attack and stroke in a broad range of high-risk patients, including diabetics (Oxford Heart Protection Study) Upcoming new chemical entity filings expected in 2003 through 2006 GABA-Aagonist • anxiety Zetia/Zocor fixed combination • elevated cholesterol levels Substance P antagonist • depression Phosphodiesterase-4 inhibitor • asthma and pulmonary disease KRP-297 • diabetes and diabetic dyslipidemia Rotavirus vaccine • prevention of infant diarrhea and dehydration caused by rotavirus HPV vaccine • human papillomavirus (HPV infection can lead to the development of cervical cancer) HIV integrase inhibitor • HIV/AIDS Selected compounds in the pipeline Herpes zoster vaccine • herpes zoster (shingles) in adults HIV vaccine • HIV/AIDS
	Arrangements complementing current therapeutic areas Cholesterol (Schering-Plough) Respiratory (Schering-Plough) HIV (Cambridge Antibody Technology, Crucell, CytRx) Antibacterials (Elitra) Osteoporosis (Celera) Ophthalmics (Cole Eye Institute) Arrangements expanding into new, large therapeutic areas Diabetes (Kyorin) Neuroscience (NeuroTargets) Influenza (Biodiem) Hepatitis C (ISIS) Arrangements for cutting-edge research technologies Pharmacogenomics (Rosetta Inpharmatics7) Genomics/Proteomics (DoubleTwist, LifeSpan, Amersham Pharmacia, Proteome) Gene Tools/Targeting (Lexicon, Sangamo, Affymetrix) Lead Identification (NeoGenesis) Assay Development (Chromagen) Chemical Libraries (Array Biopharma, Chembridge, Discovery Partners) Knock Out Mice (Deltagen, Lexicon) Arrangements for cutting-edge biologics and drug delivery technologies Drug Delivery (Elan/Nanosystems, Flamel, Symyx) Biologics (ProBioGen) 4 Merck plans to submit an expanded New Drug Application (NDA) for Arcoxia to the U.S. Food and Drug Administration in order to include new efficacy data that will better position the product to compete successfully in the coxib class, where there already are three entrants. Accordingly, on March 13, 2002, Merck withdrew the original U.S. NDA for the investigational medicine. Merck is submitting the additional efficacy data to support a new indication for ankylosing spondylitis, which is a chronic, inflammatory disorder primarily involving the spine. Timing of the expanded submission has not been determined. In addition to the indications listed above, Merck is seeking an indication for acute gouty arthritis. The regulatory process for Arcoxia outside the United States continues uninterrupted. 5 Scheduled for filing in 2002 6 Ezetimibe is under development around the globe (except in Japan) through a joint venture between Merck and Schering-Plough Corporation 7 Purchased by Merck on July 19, 2001 Back to top

		4 of 15

Copyright © 1995-2002 Merck & Co., Inc., Whitehouse Station, NJ, USA. All rights reserved.